Stupin V A, Basarbolieva Zh V, Agapov M A, Laipanov B K, Khokonov M A, Klimiashvili A D, Rodoman G V
Klin Med (Mosk). 2013;91(11):53-6.
The aim of this work was to estimate hepatic dysfunction and improve treatment of benign mechanical jaundice using an injection hepatoprotector. The study included 124 patients of whom 74 were given remaxol. 50 control subjects received basal therapy. The patients were randomized by the random sampling method. Severity of cholestasis was evaluated from the total and fractional bilirubin content and γ-glutamyl transpeptidase (GGT) level; AST and ALT activities were used to detect cytolysis. Liver synthetic function was estimated from prothrombin index (PTI) and coagulation function from fibrinogen level, PTI and APTT. Endogenous intoxication during biliary tract decompression was assessed by calculating the leukocyte intoxication index from the Kalf-Kalif formula. It was shown that remaxol suppresses cytolysis, reduces total and fractional bilirubin levels, improves bilirubin excretion in bile and decreases activity of hepatocyte excretory enzymes.
这项工作的目的是评估肝功能障碍，并使用注射用肝保护剂改善良性机械性黄疸的治疗。该研究纳入了124例患者，其中74例给予雷马克索（remaxol）。50例对照受试者接受基础治疗。患者通过随机抽样法进行随机分组。从总胆红素和分馏胆红素含量以及γ-谷氨酰转肽酶（GGT）水平评估胆汁淤积的严重程度；使用AST和ALT活性检测细胞溶解。从凝血酶原指数（PTI）评估肝脏合成功能，从纤维蛋白原水平、PTI和活化部分凝血活酶时间（APTT）评估凝血功能。通过根据卡尔夫-卡里夫公式计算白细胞中毒指数来评估胆道减压期间的内源性中毒。结果表明，雷马克索可抑制细胞溶解，降低总胆红素和分馏胆红素水平，改善胆汁中胆红素排泄，并降低肝细胞排泄酶的活性。
